After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Mylan CEO Heather Bresch holds up an EpiPen while testifying on Capitol Hill in Washington, Wednesday, Sept. 21, 2016, before the House Oversight Committee hearing on EpiPen price increases.

Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that has seen a price increase of more than 500% since 2007.

Mylan made $1.1 billion in revenue per year from EpiPen sales (though that may be decreasing with the introduction of new competition, including CVS’s generic auto-injector).

With Mylan N.V. MYL and Teva Pharmaceutical Industries Ltd. TEVA scheduled to report on May 10 and May 11, respectively, this may be a good time to consider which of these is the better stock.

Mylan has a board-election battle on its hands. Some powerful institutional investors are steamed about Mylan Chairman Robert Coury’s $97 million compensation in 2016—and they’re calling on ...

Mylan CEO Heather Bresch said she shared Americans’ frustration with the spiraling cost of drugs like her company’s EpiPen in a CNBC interview Thursday morning, but her comments hew closely to ...

D rug maker Mylan Pharmaceuticals, under fire from the public and Congress over the soaring price of its anaphylaxis treatment, will launch a generic version of the EpiPen auto-injector at a list ...

But Mylan is a generics company; it doesn’t discover new medicines. Instead, it has poured its EpiPen windfalls into marketing and lobbying in an effort to expand adoption of its banner product.